US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bayer A.G.

7.59

+0.06900.92%

Post-market: 7.590.00000.00%16:11 EDT

Volume:837.03K

Turnover:6.31M

Market Cap:29.83B

PE:-8.46

High:7.60

Open:7.48

Low:7.46

Close:7.52

Loading ...

Overview Company News Filings

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

Bayer Gets FDA Approval for Prostate-Cancer Drug

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

Bayer says FDA accepts NDA under priority review for sevabertinib

Bayer price target raised to EUR 25 from EUR 22 at Barclays

Bayer's Prospects Are Improving -- Market Talk

OTC Markets Group welcomes Bayer to OTCQX

Trump admin report implies companies are worsening health of children, FT says

Bayer reports FDA approved Jivi for use in pediatric patients 7 years and older

Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure

Bayer Q1 Adj. EPS $0.65 Beats $0.38 Estimate, Sales $14.45B Beat $13.39B Estimate

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

Bayer to Slash Hundreds of Jobs in Crop Division Overhaul

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose

Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BAYRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":7.59,"timestamp":1749240000000,"preClose":7.521,"halted":0,"volume":837032,"hourTrading":{"tag":"盘后","latestPrice":7.59,"preClose":7.59,"latestTime":"16:11 EDT","volume":549,"amount":4166.91,"timestamp":1749240699960},"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"Market Closed","change":0.069,"latestTime":"06-06 16:00:00 EDT Delay","open":7.48,"high":7.6,"low":7.46,"amount":6313842.425099995,"amplitude":0.018615,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":7.521,"volumeRatio":1.614050378597038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"2.55%","roe":"-9.49%","lyrEps":-0.672343,"volumeRatio":1.614050378597038,"shares":3929696328,"dividePrice":0.031351,"high":7.6,"amplitude":0.018615,"preClose":7.521,"low":7.46,"week52Low":4.79,"pbRate":"0.81","psRate":"0.56","week52High":8.58,"institutionHeld":0,"latestPrice":7.59,"eps":-0.897103,"divideRate":0.004131,"volume":837032,"delay":15,"ttmEps":-0.897103,"open":7.48,"prevYearClose":4.88,"prevWeekClose":7.07,"prevMonthClose":7.07,"prevQuarterClose":6.02,"fiveDayClose":7.07,"twentyDayClose":6.64,"sixtyDayClose":6.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541551042","title":"Bayer Earnings Expectations Might Have Bottomed out -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2541551042","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541551042?lang=en_us&edition=fundamental","pubTime":"2025-06-05 16:29","pubTimestamp":1749112140,"startTime":"0","endTime":"0","summary":"0829 GMT - Bayer's strong start to the year and signs of a recovery in its pharmaceutical business suggests earnings expectations might have bottomed out, Goldman Sachs analysts say in a research note. Consensus earnings estimates on the German agricultural and pharma group could start to trend higher as the market gives credit to its cost-savings plan, the analysts say. Moreover, the risk-reward equation on litigation updates through 2025 looks more favorable, according to Goldman Sachs. Legal cases over Bayer's Roundup weedkiller have been a drag on its stock since it lost the first trial in 2018, the analysts say. Goldman Sachs raises its recommendation on Bayer to buy from neutral, and lifts its target price to 33 euros from 29.10 euros. Shares jump 4.9% to 26.55 euros. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":0},{"id":"2540449088","title":"Bayer Gets FDA Approval for Prostate-Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2540449088","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540449088?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:15","pubTimestamp":1748992500,"startTime":"0","endTime":"0","summary":"Bayer said it received approval from the Food and Drug Administration for its drug Nubeqa, which treats patients with a certain type of prostate cancer.The German life-sciences company said Tuesday the approval is based on positive results from a phase 3 trial. The trial results showed a 46% reduction in the risk of radiographic progression or death among patients taking Nubeqa in combination with another form of therapy.There were 669 patients in the randomized, placebo-controlled trial, Bayer said.Nubeqa is indicated in the U.S. for the treatment of adults with metastatic and non-metastatic castration-sensitive prostate cancer.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bayer Gets FDA Approval for Prostate-Cancer Drug","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2539927883","title":"Consumer Health Sector Has Room for More Dealmaking -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2539927883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539927883?lang=en_us&edition=fundamental","pubTime":"2025-05-30 21:47","pubTimestamp":1748612820,"startTime":"0","endTime":"0","summary":"1347 GMT - The consumer-health industry could see more merger-and-acquisition activity, but smaller deals for certain brands or segments seem more likely than large-scale takeovers, Citi analysts say in a research note. Recent spinoffs such as Kenvue and Haleon, potential splits or asset reviews at Bayer and Reckitt Benckiser, and acquisition attempts like Unilever's for Haleon in 2022 left investors wondering whether the industry could consolidate, Citi says. Healthy balance sheets and interest from the likes of Procter & Gamble suggest there is room for acquisitions, but antitrust concerns and diverse portfolios make large deals unlikely, Citi says. In a large takeover, the buyer would probably need a significant portfolio reshaping afterward, the analysts say. The Stoxx Europe 600 Personal & Household Goods index is up 0.6%. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","LU0708994859.HKD","LU0029864427.USD","UN","ULVR.UK","LU0689626769.HKD","IE00B3T34201.USD","LU1267930813.SGD","PG","BK4588","IE00BFXG1179.USD","LU1267930573.SGD","BK4585","RBGLY","BK4018","LU0310800379.SGD","KVUE","BK4183","LU0889566641.SGD","BK4592","LU0792757196.USD","UL","BK4007","LU0124676726.USD","LU0128525929.USD"],"gpt_icon":0},{"id":"2539403328","title":"Bayer says FDA accepts NDA under priority review for sevabertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2539403328","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539403328?lang=en_us&edition=fundamental","pubTime":"2025-05-29 01:15","pubTimestamp":1748452511,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted the company’s new drug application and granted Priority Review desi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-says-fda-accepts-nda-under-priority-review-for-sevabertinib-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-says-fda-accepts-nda-under-priority-review-for-sevabertinib-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2538449167","title":"Bayer price target raised to EUR 25 from EUR 22 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2538449167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538449167?lang=en_us&edition=fundamental","pubTime":"2025-05-28 03:40","pubTimestamp":1748374815,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Bayer (BAYRY) to EUR 25 from EUR 22 and keeps an Equal Weight rating on the shares. Published first on T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-price-target-raised-to-eur-25-from-eur-22-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-price-target-raised-to-eur-25-from-eur-22-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2538664814","title":"Bayer's Prospects Are Improving -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2538664814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538664814?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:22","pubTimestamp":1748348520,"startTime":"0","endTime":"0","summary":"1222 GMT - Bayer is starting to show some green shoots, with a strong financial performance in the first quarter and improving prospects, Barclays analysts say in a research note. The strong first-quarter momentum for the German group, and especially for its pharma business, could continue into the rest of the year, Barclays says. New drug launches and a robust base business could lead Bayer's pharma business to exceed guidance, Barclays says. Meanwhile, Bayer's crop protection and consumer segments are on track to meet guidance despite some regulatory and profitability pressures, the analysts say. Nevertheless, the company remains in the early stages of its turnaround plan, they add. Barclays lifts its target price on Bayer to 25 euros from 22 euros. Shares rise 0.8% to 24.88 euros. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2537133743","title":"OTC Markets Group welcomes Bayer to OTCQX","url":"https://stock-news.laohu8.com/highlight/detail?id=2537133743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537133743?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:10","pubTimestamp":1747998624,"startTime":"0","endTime":"0","summary":"OTC Markets Group announced Bayer (BAYRY) has qualified to trade on the OTCQX Best Market. Bayer AG upgraded to OTCQX from the Pink market. Publish...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/otc-markets-group-welcomes-bayer-to-otcqx-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/otc-markets-group-welcomes-bayer-to-otcqx-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2537718049","title":"Trump admin report implies companies are worsening health of children, FT says","url":"https://stock-news.laohu8.com/highlight/detail?id=2537718049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537718049?lang=en_us&edition=fundamental","pubTime":"2025-05-23 18:20","pubTimestamp":1747995640,"startTime":"0","endTime":"0","summary":"The Trump administration took aim at “Big Food,” Bayer (BAYRY), Facebook (META), and other companies in its report on children’s health, blaming po...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trump-admin-report-implies-companies-are-worsening-health-of-children-ft-says-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trump-admin-report-implies-companies-are-worsening-health-of-children-ft-says-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211327993.USD","LU1066051498.USD","LU2420271590.USD","LU2250418816.HKD","LU0957808578.USD","LU0979878070.USD","LU1629891620.HKD","IE0004445239.USD","LU1778281490.HKD","LU0068578508.USD","LU1720051108.HKD","SGXZ99366536.SGD","LU0061475181.USD","LU1127390331.HKD","LU0353189680.USD","LU0256863902.USD","LU1699723380.USD","LU2430703095.HKD","BK4587","LU1564329461.SGD","BK4524","LU2756315664.SGD","BK4507","LU1670627923.USD","LU2236285917.USD","IE00B1XK9C88.USD","META","IE00B19Z3581.USD","LU2168564065.EUR","LU1732799900.SGD","SG9999015952.SGD","LU2764262908.HKD","LU1316542783.SGD","FT","IE00B1BXHZ80.USD","LU0109391861.USD","LU0208291251.USD","BAYRY","IE00B7KXQ091.USD","LU1551013425.SGD","LU0070302665.USD","GB00B4LPDJ14.GBP","LU0079474960.USD","LU0308772762.SGD","LU0149725797.USD","LU2317271919.USD","LU1267930730.SGD","LU1674673428.USD","IE00B5949003.HKD","LU0553294199.USD"],"gpt_icon":0},{"id":"2536263571","title":"Bayer reports FDA approved Jivi for use in pediatric patients 7 years and older","url":"https://stock-news.laohu8.com/highlight/detail?id=2536263571","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536263571?lang=en_us&edition=fundamental","pubTime":"2025-05-19 23:35","pubTimestamp":1747668916,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that the U.S. Food and Drug Administration has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII con...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-reports-fda-approved-jivi-for-use-in-pediatric-patients-7-years-and-older?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-reports-fda-approved-jivi-for-use-in-pediatric-patients-7-years-and-older?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2535089823","title":"Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2535089823","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535089823?lang=en_us&edition=fundamental","pubTime":"2025-05-14 03:26","pubTimestamp":1747164414,"startTime":"0","endTime":"0","summary":"Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45389381/bayer-q1-net-profit-drops-35-amid-crop-science-struggles-launches-crop-science-overhaul-to-counter-generic-pressure","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2535720427","title":"Bayer Q1 Adj. EPS $0.65 Beats $0.38 Estimate, Sales $14.45B Beat $13.39B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535720427","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535720427?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:20","pubTimestamp":1747138818,"startTime":"0","endTime":"0","summary":"Bayer (OTC:BAYRY) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.38 by 71.05 percent. This is a 15.58 percent decrease over earnings of $0.77 per share from the same period","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45373439/bayer-q1-adj-eps-0-65-beats-0-38-estimate-sales-14-45b-beat-13-39b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":0},{"id":"2535131557","title":"Bayer Shares Jump After Results Beat Expectations on Pharma Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2535131557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535131557?lang=en_us&edition=fundamental","pubTime":"2025-05-13 16:07","pubTimestamp":1747123620,"startTime":"0","endTime":"0","summary":"Bayer shares jumped after the company reported better-than-expected sales and adjusted earnings for the first quarter, with cost-cutting and demand for kidney and cancer drugs boosting its pharmaceutical business.The German pharmaceutical and agricultural company said Tuesday that it expects to be able to manage the impact of tariffs and doesn't see a need to revise its guidance. A strong pharma performance in the first quarter means that the division's full-year results are likely to hit the upper end of its full-year guidance, it said.Bayer's CEO is betting on strengthening the company's pharmaceutical pipeline to offset a weakened performance in its agricultural business during what he called a challenging but important year for the company.Sales fell 0.2% to 13.74 billion euros as higher revenue of its pharma and consumer-health businesses could not fully offset a drop in crop science. This beat a consensus forecast of 13.41 billion euros.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2535791535","title":"Bayer's Results Should Cause Positive Share Price Response -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2535791535","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535791535?lang=en_us&edition=fundamental","pubTime":"2025-05-13 14:50","pubTimestamp":1747119000,"startTime":"0","endTime":"0","summary":"0649 GMT - Bayer's results should lead to a positive share price response after the company posted better-than-expected earnings and reiterated its outlook, Jefferies analysts say in a note. The German pharmaceutical and agricultural company now forecasts its outlook for the pharma division at the upper end of its guidance range, the analysts say. Its 1Q earnings and sales topped company-compiled and Jefferies' consensus, they say. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2534827389","title":"Bayer to Slash Hundreds of Jobs in Crop Division Overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=2534827389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534827389?lang=en_us&edition=fundamental","pubTime":"2025-05-12 21:15","pubTimestamp":1747055700,"startTime":"0","endTime":"0","summary":"Bayer plans to cut hundreds of jobs as part of an overhaul of its crop division in Germany.The German pharmaceutical company said Monday that it will discontinue the production of active ingredients of crop protection products at its Dormagen site, which are available at lower prices on the global market, resulting in 200 job cuts. Its Dormagen site currently employs around 1200 staff.It will also cut production activities at the Frankfurt am Main site, which develops  herbicide active ingredients and formulations. The company plans to sell parts of these operations, while others will be relocated to existing production sites. Frankfurt am Main currently employs around 500 people, but Bayer said not all employees would be affected by cuts.\"We are committed to Germany. However, to live up to this commitment in times of considerable challenges, we need to adjust,\" said Frank Terhorst, head of strategy at Bayer's crop science division.The Bayer General Works Council and chemical union IGB","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2527247077","title":"DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2527247077","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527247077?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:52","pubTimestamp":1744807920,"startTime":"0","endTime":"0","summary":"Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast Track designation to PBGENE-HBV. This is DTIL’s lead, fully owned in vivo gene editing program aimed at curing chronic hepatitis B by eliminating cccDNA — the primary source of replicating hepatitis B virus  — and inactivating integrated HBV DNA in liver cells .The FDA’s Fast Track designation is intended to speed up the development and review of drugs that treat serious conditions and fulfill unmet medical needs. It offers benefits, such as more frequent FDA interactions, rolling submission of marketing applications, and potential eligibility for Priority Review if certain conditions are met.According to Precision BioSciences, PBGENE-HBV is the first and only gene editing program with this unique mechanism of action to enter the clinical stage as a potential cure.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dtil-gets-fdas-fast-track-125200444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFXG0V08.USD","BK4588","IE00BYQQ9H92.USD","BK4104","BK4567","FAST","BK4007","BAYRY","DTIL","BK4139","DVAX","BK4585","IE00B5TLWC47.USD","ADMA"],"gpt_icon":0},{"id":"2527290404","title":"VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290404","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290404?lang=en_us&edition=fundamental","pubTime":"2025-04-16 00:27","pubTimestamp":1744734420,"startTime":"0","endTime":"0","summary":"Shares of Verve Therapeutics VERV surged 26.4% on Monday and continue to soar today after the company announced positive initial datafrom an early-stage study of its investigational candidate, VERVE-102, which is being developed for reducing cholesterol levels. VERVE-102 is a novel,in vivo, investigational base editing medicine.The data readout includes 14 patients from the first three cohorts who received doses of VERVE-102 at 0.3 mg/kg, 0.45 mg/kg, or 0.6 mg/kg, respectively, with each participant having at least 28 days of follow-up as of the data cutoff date of March 13, 2025.More on VERV’s Phase I Cholesterol Drug Study Data. Verve Therapeutics reported that a single infusion of VERVE-102 resulted in dose-dependent reductions in blood PCSK9 protein levels and LDL-C in the Heart-2 study, with an average LDL-C decrease of 53% and a maximum reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verv-stock-soars-superior-efficacy-162700742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0640476718.USD","GB00BDT5M118.USD","LU2360106947.USD","LU2471134879.HKD","LU0094547139.USD","LU1720051108.HKD","IE00BK4W5L77.USD","ADMA","LU2237443549.SGD","LU0820561909.HKD","SG9999015986.USD","LU1551013425.SGD","SG9999001176.SGD","LU1868836757.USD","LU0122379950.USD","LU0079474960.USD","IE00BK4W5M84.HKD","LU0198837287.USD","LU1127390331.HKD","LU2324357040.USD","LU2491050071.SGD","LU2491050154.USD","SGXZ81514606.USD","LU1035775433.USD","LU1093756325.SGD","LU2063271972.USD","LU2089984988.USD","IE0009355771.USD","LU1712237335.SGD","LU0106261372.USD","LU1023059063.AUD","LU0943347566.SGD","LLY","LU1280957306.USD","LU2468319806.SGD","LU2357305700.SGD","BK4588","LU1093756168.USD","LU1720051017.SGD","BK4585","LU0058720904.USD","LU2023250504.SGD","LU0320765059.SGD","LU0238689110.USD","LU0672654240.SGD","VERV","LU2471134796.USD","BAYRY","SG9999015978.USD","LU1623119135.USD"],"gpt_icon":1},{"id":"2527524165","title":"Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2527524165","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527524165?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:00","pubTimestamp":1744635600,"startTime":"0","endTime":"0","summary":"Pharmaceutical and agriculture conglomerate Bayer said it could stop producing the world's most popular weedkiller, unless it gets court protection against lawsuits blaming the herbicide for causing cancer.Roundup has generated tens of billions of dollars in sales over time for Bayer and Monsanto, the biotech seed giant and developer of Roundup that Bayer acquired in 2018. Bayer currently produces about 40% of the world's glyphosate, which farmers spray across fields to tame crop-threatening weeds.But over the past decade, the herbicide has also brought Bayer a wave of litigation, pressuring its share price and costing about $10 billion in payouts to plaintiffs. In early March, Bayer told farmers, suppliers and retailers that it may stop selling Roundup, which would leave U.S. farmers reliant on imported glyphosate from China.\"We're pretty much reaching the end of the road,\" Bayer Chief Executive Bill Anderson said in an interview. \"We're talking months, not years.\". Since taking over ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2526761082","title":"NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2526761082","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526761082?lang=en_us&edition=fundamental","pubTime":"2025-04-12 01:17","pubTimestamp":1744391820,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis NVS announced a planned $23 billion investment over five years in U.S.-based infrastructure.Backed by this investment, the company intends to manufacture all key drugs for its U.S. patients in the country.NVS' decision to expand its current manufacturing, research and technology presence across the country follows President Trump's announcement of tariffs on pharmaceutical imports.The company's shares are up in pre-market. Novartis’ shares have risen 8.7% year to date against the industry’s decline of 8.2%.NVS expanded its manufacturing and R&D presence in the country by investing in 10 facilities, including seven brand-new ones.Over the next five years, Novartis will establish a biomedical research innovation hub in San Diego, CA, its second global R&D hub in the United States. This is expected to open during 2028-2029.These investments will ensure Novartis has manufacturing capacity in the United States for all its core technology platforms, including smal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvs-plans-invest-23b-us-171700008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","IE00BJT1NW94.SGD","LU0208291251.USD","LU0320765489.SGD","BAYRY","BK4578","LU0211331839.USD","BK4007","BK4588","BK4532","LU0070302665.USD","BK4585","NVS","ADMA","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4139","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2526511532","title":"PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2526511532","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526511532?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:53","pubTimestamp":1744296780,"startTime":"0","endTime":"0","summary":"Shares of Phio Pharmaceuticals PHIO rallied 52.5% on Wednesday after the company announced that the Safety Monitoring Committee  has recommended dose escalation in an early-stage study of the company’s investigational skin cancer candidate, PH-762.PH-762 is Phio Pharmaceuticals’ lead and only clinical-stage candidate, which is being developed leveraging its proprietary IntasylsiRNA gene silencing technology to eliminate cancer. The phase Ib dose escalation study is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.The SMC’s decision allowing escalation to the next dose concentration was based on the favorable safety profile of the drug observed in the third cohort of the phase Ib study, which enrolled three patients with cutaneous squamous cell carcinoma. In these patients, injections were well tolerated, with no serious adverse events or dose-limiting toxicities. Pathology results a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-stock-soars-safety-panel-145300505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","DVAX","SMC","BK4139","PHIO","BK4144","BK4007","BAYRY"],"gpt_icon":0},{"id":"2526899425","title":"Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526899425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526899425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 15:36","pubTimestamp":1744270560,"startTime":"0","endTime":"0","summary":"0736 GMT - European pharma stocks jump at Thursday's market open, mirroring broader market gains, after U.S. President Trump announced a 90-day pause on so-called reciprocal tariffs. The Stoxx 600 health index surges around 7.2%, outpacing the wider Stoxx 600's 1.2% rise. While pharmaceuticals have so far been spared, Trump reiterated on Tuesday that tariffs on imported medicines remain a possibility. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","IE00B4R5TH58.HKD","LU0320765992.SGD","BAYRY","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00B2B36J28.USD","LU0070302665.USD","NVS","BK4007","BK4532","LU0109394709.USD","SNY","03165","LU0208291251.USD","LU0320765489.SGD","AZN","LU2456880835.USD","LU2462157665.USD","IE0009355771.USD","RHHBY","IE00BFTCPJ56.SGD","LU0211331839.USD","GSK","IE00BFXG1179.USD","BK4588","BK4585","GSK.UK","LU1829250122.USD","LU2417539215.USD","LU2236285917.USD","IE00BJT1NW94.SGD","BK4578"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}